After Fine, Botox Awaits F.D.A. Approval for Migraine
Allergan agreed to pay $ 600 million for Botox’s marketing getting ahead of approved uses. But the F.D.A. will soon decide on its effectiveness for chronic migraines.
Read more on New York Times
After Fine, Botox Awaits F.D.A. Approval for Migraine
Allergan agreed to pay $ 600 million for Botox’s marketing getting ahead of approved uses. But the F.D.A. soon will be deciding on its effectiveness in chronic migraines.
Read more on New York Times
Related posts:
- Latest Botox News
- Latest Botox News
- Teens using Botox are upsetting but rare
- Collins: ‘I’ve nothing against Botox’
- Botox…..?